Publications by authors named "Fortunato Morabito"

Relapsed and refractory multiple myeloma (RRMM) remains a challenging condition despite advances in immunotherapies. Novel bispecific antibodies (BsAbs), including talquetamab, have shown promising efficacy in heavily pretreated patients, even those with triple- and penta-refractory disease. Talquetamab, recently approved by the FDA and EMA, is indicated for patients who have progressed after at least three or four prior lines of therapy (LOTs).

View Article and Find Full Text PDF

This study aimed to assess whether multidisciplinary team (MDT) management improves outcomes in patients with stage I-III colorectal cancer (CRC) compared to non-MDT care. This study included 460 CRC patients diagnosed from 2017 to 2018 in a northern Italian province, of whom 300 (65%) were managed by MDT. MDT patients were younger, more frequently had rectal cancers, were diagnosed at earlier stages, and were more likely to undergo surgery and chemotherapy.

View Article and Find Full Text PDF

Purpose: This study aimed to develop a multivariable, weighted overall survival (OS) risk score (SRS) for nonmetastatic (M0) invasive breast cancer (M0-BC, SRS).

Materials And Methods: This study included a training (1,890 patients) and a validation cohort (850 patients) from the Reggio Emilia Cancer Registry (RE-CR). Ten traditional prognostic variables were evaluated.

View Article and Find Full Text PDF

The treatment landscape for relapsed/refractory follicular lymphoma (RR-FL) is marked by a pivotal debate between chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAbs). While both CAR-T therapy and BsAbs target similar immunobiology and molecular markers, their efficacy comparisons are hindered by the lack of direct clinical trial comparisons. Key trials, such as the ZUMA-5 study, underscore axicabtagene ciloleucel (axi-cel)'s efficacy in treating RR-FL, achieving a 79% complete response rate with a median duration of response exceeding 3 years.

View Article and Find Full Text PDF

International studies have shown an increase in cancer incidence among young adults, raising public concern. This study aims examines trends in the cancer incidence among individuals aged 15-49 years in a province of Northern Italy, covering diagnoses from 1996 to 2021, and compares the annual percentage change (APC) with national and international data. In males, the overall cancer incidence showed a modest increase between 1996 and 2013 (APC 1.

View Article and Find Full Text PDF
Article Synopsis
  • Therapy-related acute promyelocytic leukemia (t-APL) is a rare condition often arising from treatments like alkylating agents or topoisomerase II inhibitors.
  • The report details three cases of t-APL at Cosenza Hospital, each requiring unique treatments following different cancer therapies.
  • Notable outcomes include a complete remission in one patient treated with ATRA, while another faced severe complications but also achieved remission; the third patient, however, sadly died due to complications during treatment.
View Article and Find Full Text PDF
Article Synopsis
  • Myelofibrosis (MF) is a blood disorder characterized by bone marrow fibrosis and splenomegaly, with potential therapeutic benefits from steroids due to their anti-inflammatory properties, particularly for managing anemia and cytopenias.
  • Clinical studies are evaluated regarding the safety and effectiveness of steroids in MF, including their use alongside immunomodulatory agents and JAK inhibitors.
  • Expert opinions suggest that while the role of steroids in MF treatment is not fully understood, they may offer benefits in alleviating anemia and improving patient outcomes, especially when combined with other treatments.
View Article and Find Full Text PDF

A "watch and wait" strategy, delaying treatment until active disease manifests, is adopted for most CLL cases; however, prognostic models incorporating biomarkers have shown to be useful to predict treatment requirement. In our prospective O-CLL1 study including 224 patients, we investigated the predictive role of 513 microRNAs (miRNAs) on time to first treatment (TTFT). In the context of this study, six well-established variables (i.

View Article and Find Full Text PDF

Introduction: Follicular lymphoma (FL) is an indolent non-Hodgkin lymphoma that shows a progressive increase in relapses and refractory in its natural history and a median survival of approximately 18-20 years. The advent of anti-CD20 monoclonal antibodies has changed the FL therapeutic algorithm, with an increase in progression-free survival. T-cell-dependent bispecific antibodies (BsAbs) represent an emerging drug class against FL.

View Article and Find Full Text PDF

Introduction: CXCR4/CXCL12 axis regulates cell proliferation, survival, and differentiation, as well as the homing and mobilization of hematopoietic stem cells (HSCs) from bone marrow niches to the peripheral blood. Furthermore, CXCR4 and CXCL12 are key mediators of cross-talk between hematological malignancies and their microenvironments. CXCR4 overexpression drives disease progression, boosts tumor cell survival, and promotes chemoresistance, leading to poor prognosis.

View Article and Find Full Text PDF

The COVID-19 pandemic has caused delays in cancer diagnoses and reductions in treatments. The aim of this work is to evaluate the impact of the pandemic on prostate cancer by evaluating whether there has been a shift towards more aggressive (Gleason) and more advanced tumors (stage IV) and a decline in treatments. The study was conducted on 1123 cases of prostate cancer incident in the Province of Reggio Emilia, Northern Italy, in the period of 2018-2021.

View Article and Find Full Text PDF

Colorectal cancer emerged as the third most prevalent malignancy worldwide, affecting nearly 2 million individuals in the year 2020. This study elucidates the pivotal role of a multidisciplinary team (MDT) in influencing the prognosis, as measured by relative survival rates, depending upon the stage and age. Cases recorded in an Italian Cancer Registry between 2017 and 2018 were included.

View Article and Find Full Text PDF

Enhanced Recovery After Surgery (ERAS) protocols have changed perioperative care, aiming to optimize patient outcomes. This study assesses ERAS implementation effects on postoperative complications, length of hospital stay (LOS), and mortality in colorectal cancer (CRC) patients. A retrospective real-world analysis was conducted on CRC patients undergoing surgery within a Northern Italian Cancer Registry.

View Article and Find Full Text PDF
Article Synopsis
  • - The ELOQUENT-3 trial found that the combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) is more effective and safer than pomalidomide and dexamethasone (Pd) for treating relapsed/refractory multiple myeloma (RRMM) patients who have undergone at least two prior therapies.
  • - An 18-month follow-up of 319 RRMM patients treated with EloPd in Italy revealed that 66.4% experienced disease progression or death, with median progression-free survival and overall survival recorded at 7.5 and 19.2 months, respectively.
  • - While EloPd remains a viable treatment option,
View Article and Find Full Text PDF

Introduction: Gain/amplification of 1q (+1q) represents one of the most prevalent cytogenetic abnormalities (CAs) observed in multiple myeloma (MM). Historical studies predating the advent of anti-CD38 monoclonal antibodies (moAbs) implicated + 1q in poor prognoses, prompting its integration into novel staging systems. However, with the emergence of daratumumab and isatuximab, two pivotal anti-CD38 moAbs, the landscape of MM therapy has undergone a profound transformation.

View Article and Find Full Text PDF
Article Synopsis
  • Acute myeloid leukemia (AML) includes various aggressive blood cancers, with FLT3 mutations found in 25-30% of adult cases, leading to poor outcomes and a high chance of relapse.
  • The review highlights current treatment methods for FLT3 AML, including data on combination therapies that incorporate FLT3 inhibitors.
  • It also addresses the issue of drug resistance, the importance of tailored treatment for patients unable to undergo intensive chemotherapy, and discusses key FLT3 inhibitors like midostaurin, gilteritinib, and quizartinib, along with ongoing studies of new triplet combinations.
View Article and Find Full Text PDF
Article Synopsis
  • Myelofibrosis (MF) is a bone marrow disease marked by fibrosis, low blood cell counts, enlarged spleen, and other symptoms, with existing treatments like ruxolitinib and fedratinib posing challenges mainly due to anemia.
  • Momelotinib (MMB) is a promising JAK inhibitor that not only targets disease symptoms but also improves anemia by inhibiting specific kinases and reducing inflammatory cytokines.
  • Clinical trials indicate that MMB effectively reduces spleen size and symptoms, presenting a safer alternative to traditional treatments, and ongoing research is looking into its broader applications in hematologic cancers.
View Article and Find Full Text PDF

Introduction: Selinexor, an XPO1 inhibitor, has emerged as a promising therapeutic option in the challenging landscape of relapsed/refractory multiple myeloma (RRMM).

Areas Covered: This article provides a review of selinexor, with a focus on available clinical studies involving MM patients and its safety profile. Clinical trials, such as STORM and BOSTON, have demonstrated its efficacy, particularly in combination regimens, showcasing notable overall response rates (ORR) and prolonged median progressionfree survival (mPFS).

View Article and Find Full Text PDF
Article Synopsis
  • * Patients with del(5q) typically show symptoms like anemia and have a lower risk of progressing to acute leukemia, classified as a specific subtype by the World Health Organization.
  • * The deletion impacts various genes in chromosome 5, making MDS cells sensitive to the drug lenalidomide, although responses vary, resulting in ongoing research to understand the biology behind the disease and improve treatment outcomes.
View Article and Find Full Text PDF

Although chronic lymphocytic leukemia (CLL) predominantly affects the elderly, limited data exists about the outcomes of over 80-year-old patients, usually underrepresented in clinical trials. We conducted a multicenter study enrolling 79 consecutive CLL patients ≥80 years at the time of frontline therapy, all treated with ibrutinib. Nearly 48% of cases exhibited unmutated IGHV genes, 32% 17p deletion, and 39.

View Article and Find Full Text PDF